Fig. 7: Schematic diagram shows the mechanisms of how the CRC cells’ resistance to oxaliplatin and ML264 restores oxaliplatin sensitivity of colorectal cancer.
Overexpression of KLF5 and its downstream anti-apoptotic factor Bcl-2 was one of the mechanisms for CRC to resist oxaliplatin.
